Apply to trial NCT07734103

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder

The primary objective of this study is to evaluate the efficacy and tolerability of Lumateperone in reducing stuttering symptoms. The following scales and samples will be collected for clinical and functional outcomes. • MLGSSS • SSS • Stuttering Severity Instrument (SSI-IV) • PHQ-9 • Barnes Akathisia • SAS • AIMS • CGI-I • CGI-S

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening